[go: up one dir, main page]

AR045326A1 - Derivados de aminoquinolina y su uso como ligandos a3 de adenosina - Google Patents

Derivados de aminoquinolina y su uso como ligandos a3 de adenosina

Info

Publication number
AR045326A1
AR045326A1 ARP040102713A ARP040102713A AR045326A1 AR 045326 A1 AR045326 A1 AR 045326A1 AR P040102713 A ARP040102713 A AR P040102713A AR P040102713 A ARP040102713 A AR P040102713A AR 045326 A1 AR045326 A1 AR 045326A1
Authority
AR
Argentina
Prior art keywords
group
atom
branched
linear
alkyl
Prior art date
Application number
ARP040102713A
Other languages
English (en)
Inventor
Peter Aranyi
Sandor Batori
Geza Timari
Kinga Boer
Zoltan Kapui
Endre Mikus
Katalin Urban Szabo
Katalin Gerber
Judit Vargane Szeredi
Michel Finet
Original Assignee
Sanofi Aventis
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from HU0302440A external-priority patent/HUP0302440A3/hu
Priority claimed from HU0401467A external-priority patent/HUP0401467A3/hu
Priority claimed from HU0401468A external-priority patent/HUP0401468A3/hu
Application filed by Sanofi Aventis filed Critical Sanofi Aventis
Publication of AR045326A1 publication Critical patent/AR045326A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4706—4-Aminoquinolines; 8-Aminoquinolines, e.g. chloroquine, primaquine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
    • A61P5/40—Mineralocorticosteroids, e.g. aldosterone; Drugs increasing or potentiating the activity of mineralocorticosteroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C229/00—Compounds containing amino and carboxyl groups bound to the same carbon skeleton
    • C07C229/46—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino or carboxyl groups bound to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton
    • C07C229/50—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino or carboxyl groups bound to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton with amino groups and carboxyl groups bound to carbon atoms being part of the same condensed ring system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C07D215/54—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 3
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Neurology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Endocrinology (AREA)
  • Urology & Nephrology (AREA)
  • Pain & Pain Management (AREA)
  • Epidemiology (AREA)
  • Psychology (AREA)
  • Emergency Medicine (AREA)
  • Vascular Medicine (AREA)
  • Hematology (AREA)
  • Rheumatology (AREA)
  • Obesity (AREA)
  • Dermatology (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Quinoline Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Compuestos de la fórmula general (1), donde R1 representa un átomo de H o un grupo alquilo C1-4 lineal o ramificado; R2 representa un átomo de H o un grupo alquilo C1-4 lineal o ramificado; R3 representa un átomo de H, o un grupo alquilo C1-4 lineal o ramificado, un grupo cicloalquilo C3-6, un grupo fenilo, tienilo o furilo, opcionalmente sustituido con uno o más grupos alquilo c1-4 lineal o ramificado, un grupo alcoxi C1-4 lineal o ramificado o un átomo de halógeno; un grupo heteroaromático de 6 o 5 miembros que contiene 1, 2 o 3 átomos de N, o un anillo heteroaromático de 5 miembros que contiene un átomo de N y un átomo de O, o un átomo de N y un átomo de S, opcionalmente sustituido con 1 o más grupos alquilo C1-4 lineal o ramificado, un grupo alcoxi C1-4 lineal o ramificado, o un átomo de halógeno; R4 y R5 representan en forma independiente un átomo de H, un grupo cicloalquilo C3-6, un grupo alquilo C1-4 lineal o ramificado que contiene opcionalmente un grupo amino, o un grupo amino sustituido con 1 o 2 grupos alquilo C1-4 lineal o ramificado, un grupo hidroxi, un grupo carboxi o un grupo alcoxi sustituido con un grupo alquilo c1-4 lineal o ramificado; o R4 representa un átomo de H o un grupo alquilo C1-4 lineal o ramificado o un grupo bencilo, y R5 representa un átomo de H, un grupo -SO2OH o un grupo acilo C1-4 lineal o ramificado, o r4 y R5, junto con el átomo de N, forman un grupo de fórmula general (2), donde R7 y R8 representan en forma independiente un átomo de H, un grupo alquilo C1-4 lineal o ramificado o un grupo cicloalquilo C3-6; R6 representa un átomo de H o un grupo alquilo C1-4 lineal o ramificado, un grupo fenilo, bencilo, tienilo o furilo, opcionalmente sustituido con 1 grupo metilendioxi, o con 1 o más grupos alquilo C1-4 lineal o ramificado, un grupo alcoxi C1-4 lineal o ramificado, un grupo hidroxi, un grupo trifluorometilo, un grupo ciano o un átomo de halógeno; o un grupo heteroaromático de 6 o 5 miembros que contiene 1, 2 o 3 átomos de N, o un átomo de N y un átomo de O, o un átomo de N y un átomo de S, opcionalmente sustituido con 1 o más grupos alquilo C1-4 lineal o ramificado, un grupo C1-4 alcoxi lineal o ramificado o un átomo de halógeno; X representa un grupo -CH2-, un grupo -NH-, un grupo -NR9-, o un átomo de S, un átomo de O, un grupo sulfo o un grupo sulfoxi, donde R9 representa un grupo alquilo C1-4 lineal o ramificado o un grupo cicloalquilo C3-6; Z representa un átomo de O, un átomo de S, un grupo -CHR10- o un grupo -NR11-, donde R10 representa un átomo de H, un grupo C1-4 alquilo lineal o ramificado, o un grupo cicloalquilo C3-6 y R11 representa un átomo de H, un grupo alquilo C1-4 lineal o ramificado, un grupo cicloalquilo C3-6, un grupo -SO2OH o un grupo acilo C1-4 lineal o ramificado; n representa 0, 1 o 2; m representa 1, 2 o 3; o representa 1, 2 o 3; p representa 0 o 1; r representa 0 o 1; y sus sales, solvatos, isómeros (por tautomería, desmotropía, isómeros ópticamente activos) así como sus sales y solvatos, que son fuertes ligandos, preferentemente antagonistas del receptor de adenosina A3.
ARP040102713A 2003-07-31 2004-07-30 Derivados de aminoquinolina y su uso como ligandos a3 de adenosina AR045326A1 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
HU0302440A HUP0302440A3 (en) 2003-07-31 2003-07-31 Aminoquinoline derivatives, process for producing them and pharmaceutical compositions containing them
HU0401467A HUP0401467A3 (en) 2004-07-21 2004-07-21 Aminoquinoline derivatives, process for producing them and their use as adenosine a3 ligands
HU0401468A HUP0401468A3 (en) 2004-07-21 2004-07-21 Aminoquinoline derivatives and process for producing them

Publications (1)

Publication Number Publication Date
AR045326A1 true AR045326A1 (es) 2005-10-26

Family

ID=90001697

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP040102713A AR045326A1 (es) 2003-07-31 2004-07-30 Derivados de aminoquinolina y su uso como ligandos a3 de adenosina

Country Status (24)

Country Link
US (4) US7547696B2 (es)
EP (1) EP1663982B1 (es)
JP (1) JP2007500689A (es)
KR (1) KR20060065662A (es)
AR (1) AR045326A1 (es)
AU (1) AU2004259127B2 (es)
BR (1) BRPI0412577A (es)
CA (1) CA2534105C (es)
CY (1) CY1107875T1 (es)
DE (1) DE602004010284T2 (es)
DK (1) DK1663982T3 (es)
ES (1) ES2295923T3 (es)
HR (1) HRP20070584T3 (es)
IL (1) IL173416A (es)
MA (1) MA27991A1 (es)
ME (1) MEP19108A (es)
MX (1) MXPA06001254A (es)
NO (1) NO20060702L (es)
NZ (1) NZ545580A (es)
PL (1) PL1663982T3 (es)
PT (1) PT1663982E (es)
RS (1) RS20060072A (es)
TW (1) TW200510320A (es)
WO (1) WO2005009969A1 (es)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUP0400812A2 (en) * 2004-04-19 2006-02-28 Sanofi Aventis Crystalline forms of 2-amino-3-cyano-quinoline derivatives, process for their preparation and pharmaceutical compositions containing them
WO2006023158A2 (en) 2004-07-14 2006-03-02 Ligand Pharmaceuticals, Inc. Mineralocorticoid receptor modulator compounds and methods, and pharmaceutical compositions containing these compounds
WO2006010142A2 (en) 2004-07-14 2006-01-26 Ligand Pharmaceuticals, Inc. Mineralocorticoid receptor modulator compounds, processes for their preparation, and their use
DE502006002829D1 (de) * 2005-06-01 2009-03-26 Clariant Produkte Deutschland -methyl)-1,1-bis(pyridin-2-yl)-1-aminoalkan-verbindungen und diese verbindungen enthaltende metallkomplex-salze
EP1901744A2 (en) * 2005-06-28 2008-03-26 Bausch & Lomb Incorporated Preparations comprising arylazine substituted with a carbonylic moiety to increase the activity of gelatinase a in ocular cells
DE602007012904D1 (de) * 2006-06-27 2011-04-14 Cbt Dev Lim Neue 2',3'-methylidenacetyladenosine prodrugs zur
MX297306B (es) 2006-11-22 2012-03-22 Ajinomoto Kk Procedimiento para la produccion de derivados de fenilalanina que tienen estructuras de base de quinazolinodiona e intermediarios para la produccion.
HUP0700395A2 (en) * 2007-06-07 2009-03-02 Sanofi Aventis Substituted [1,2,4] triazolo [1,5-a] quinolines, process for their preparation, pharmaceutical compositions thereof, and intermediates
JP2012051803A (ja) * 2008-12-25 2012-03-15 Kyorin Pharmaceutical Co Ltd 環状アミノ安息香酸エステル誘導体の製造方法
EP2504330A1 (en) 2009-11-23 2012-10-03 Amgen Inc. Amino heteroaryl compounds as beta-secretase modulators and methods of use
US9296698B2 (en) 2009-11-23 2016-03-29 Amgen Inc. Amino heteroaryl compounds as beta-secretase modulators and methods of use
EP2526092B1 (en) 2010-01-19 2014-08-06 Amgen Inc. Amino heteroaryl compounds as beta-secretase modulators and methods of use
ES2578363B1 (es) 2015-01-22 2017-01-31 Palobiofarma, S.L. Moduladores de los receptores A3 de adenosina
UY36838A (es) 2015-08-03 2017-01-31 Bristol Myers Squibb Company Una Corporación Del Estado De Delaware Compuestos heterocíclicos moduladores de la señalización de tnf alfa y composiciones farmacéuticas que los contienen
ES2676535B1 (es) 2017-01-20 2019-04-29 Palobiofarma Sl Moduladores de los receptores a3 de adenosina

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9300059D0 (en) 1992-01-20 1993-03-03 Zeneca Ltd Quinazoline derivatives
UA73073C2 (uk) 1997-04-03 2005-06-15 Уайт Холдінгз Корпорейшн Заміщені 3-ціанохіноліни, спосіб їх одержання та фармацевтична композиція
WO2000061556A1 (en) 1999-04-09 2000-10-19 Meiji Seika Kaisha, Ltd. Nitrogen-containing heterocyclic compounds and benamide compounds and drugs containing the same
SK14142003A3 (sk) * 2001-05-31 2005-03-04 Sanofi-Aventis Aminochinolínové a aminopyridínové deriváty a ich použitie ako adenozínových A3 ligandov

Also Published As

Publication number Publication date
US20110112092A1 (en) 2011-05-12
MEP19108A (en) 2010-06-10
CY1107875T1 (el) 2013-06-19
US7799922B2 (en) 2010-09-21
PL1663982T3 (pl) 2008-03-31
MXPA06001254A (es) 2006-05-17
CA2534105A1 (en) 2005-02-03
HK1088261A1 (en) 2006-11-03
CA2534105C (en) 2012-02-21
US20110009626A1 (en) 2011-01-13
TW200510320A (en) 2005-03-16
US20090247745A1 (en) 2009-10-01
EP1663982B1 (en) 2007-11-21
IL173416A (en) 2011-03-31
IL173416A0 (en) 2006-06-11
AU2004259127B2 (en) 2009-05-28
HRP20070584T3 (hr) 2008-01-31
NZ545580A (en) 2009-03-31
ES2295923T3 (es) 2008-04-16
MA27991A1 (fr) 2006-07-03
KR20060065662A (ko) 2006-06-14
US8071601B2 (en) 2011-12-06
DK1663982T3 (da) 2008-03-17
NO20060702L (no) 2006-02-28
US20060211689A1 (en) 2006-09-21
PT1663982E (pt) 2008-01-31
JP2007500689A (ja) 2007-01-18
WO2005009969A1 (en) 2005-02-03
AU2004259127A1 (en) 2005-02-03
EP1663982A1 (en) 2006-06-07
US7547696B2 (en) 2009-06-16
DE602004010284T2 (de) 2008-10-02
DE602004010284D1 (de) 2008-01-03
BRPI0412577A (pt) 2006-09-19
RS20060072A (sr) 2008-08-07

Similar Documents

Publication Publication Date Title
AR045326A1 (es) Derivados de aminoquinolina y su uso como ligandos a3 de adenosina
AR055144A1 (es) Inhibidor de secrecion acida
ES2308299T3 (es) Tiadiazoles como ligandos de receptores de cxc-y cc-quimioquinas.
CO5640117A2 (es) Derivados de 2,4-diamonopirimidina
CY1108744T1 (el) 2-οξο-1,2,4,5-τετραϋδρo-1,3-βενζοδιαζεπιν-3-υλ-πιπεριδινες ως ανταγωνιστες της cgrp
CR9459A (es) Derivados benzodioxano y benzodioxolano y usos de los mismos
AR055150A1 (es) Compuestos de isoindol - imido y composiciones que los comprenden y sus metodos de uso
CO6150140A2 (es) Inhibidores de proteina tirosina fosfatasa humana y metodos de uso
AR072166A1 (es) Derivado de piperidina y su uso como inhibidor de renina superior
AR058769A1 (es) Inhibidores de peptidil-deformilasa(pdf),utiles para el tratamiento de la tuberculosis y composiciones farmaceuticas que los contienen.
CO6150144A2 (es) Inhibidores de proteina tirosina fosfatasa humana y metodos de uso
CO6231028A2 (es) Compuestos y composiciones como inhibidores de la proteina quinasa
AR053329A1 (es) Derivados de indol utiles como inhibidores de los transportadores de glucosa dependientes del sodio (sglt)
CO5580788A2 (es) Compuestos de bencimidazol sustituidos utiles como inhibidores de proteina cinasas
UY29176A1 (es) Derivados sustituidos de purina, purinona y deazapurina, composiciones que los contienen, métodos para su preparación y sus usos.
AR061739A1 (es) Nuevos derivados naftalenicos, su procedimiento de preparacion y las composiciones farmaceuticas que los contienen
AR049125A1 (es) Heterociclos biciclicos nitrogenados inhibidores de la aromatasa.
PE20061164A1 (es) Piperazin-piperidinas sustituidas con pirazinilo con actividad antagonista de cxcr3
CO5031253A1 (es) Antagonistas receptores y5 de neuropeptidos composiciones farmaceuticas que las contienen
ECSP088149A (es) 3-acilaminobenzanilidas insecticidas
CO5700754A2 (es) Derivados de piperazina y su uso en el tratamiento de enfermedades neurologicas y psiquiatricas
AR052943A1 (es) Derivados de 2-(4-oxo-4h-quinazolin-3-il)acetamida
AR052568A1 (es) Derivados de pirazolo -pirimidina como antagonstas de mglur2
DE602007004740D1 (de) Antibiotische spiroderivate
AR066873A1 (es) Derivados de triazolo (1,5-a) quinolina, procesos de obtencion y composiciones farmaceuticas

Legal Events

Date Code Title Description
FA Abandonment or withdrawal